Hapten-enhanced personalized chemoimmunotherapy by intratumoral drug delivery in advanced pancreatic cancer.

Abstract

333 Background: Currently cancer therapy is not satisfied with the effectiveness of available treatment. Engaging the power of immune system of individual patient has been considered as a highly attractive way for cancer treatment. Sipuleucel-T is an autologous cellular vaccine and represents a significant milestone for cancer immunotherapy. To evaluate the clinical effective of hapten enhanced personalized chemoimmunotherapy by intratumoral delivery of a combined drugs solution called ChemoCancerVac (CCV) in the treatment of advance pancreatic cancer and further to analyze the effect of immune adjuvant. Methods: Introtumoral injection of CCV into late stages of pancreatic cancer (92 cases), which is a proprietary therapeutic regimen composed of three components for modulation of chemoimmunotherapy, i.e. an oxidant, a cytotoxic drug and a hapten. The patients (47 patients with effect analysis and 45 patients with complete survival data were randomly divided into two groups: introtumoral chemotherapy (ITCT) alone received the CCV without hapten and introtumoral chemoimmunotherapy (ITCIT) received the CCV with the hapten. Results: In the ITCT and ITCIT groups, the clinical response rates were 92.86% and 82.88%, the median survival time and 6-month survival rate were 6.45 months vs 4.98 months and 45% vs 64%, respectively. All of mentioned above were showed no statistical difference (p>0.05), whereas 1-year survival rate of the ITCT group was 5% while that of ITCiT group was 28%. The difference was significant (p<0.05). Conclusions: The hapten enhanced personerlized immunotherapy by intratumoral injection of CCV was effective in the pancreatic cancer, meanwhile, the hapten plays an important role in prolong the patient survival time which are valuable in the clinic application.